Select studies have explored the single agent efficacy of TGFβ signal inhibition in mouse models of advanced PDAC; however, such approaches fail to significantly evoke a functional anti-tumor immune response or enhance survival [148,149]. The gene discussed is TGFB1; the disease is neoplasm.